97620671 - RENEGADE THERAPEUTICS

Information

• Trademark
• 97620671

• Source

• Serial Number

  97620671

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 5 - Pharmaceutical and veterinary preparations
  • 42 - Scientific and technological services and research and design relating thereto

• Filing Date

  October 05, 2022
  2 years ago

• Transaction Date

  July 31, 2024
  6 months ago

• Status Date

  July 31, 2024
  6 months ago

• Published for Opposition Date

  December 19, 2023
  a year ago

• Location Date

  February 13, 2024
  12 months ago

• Status Code

  730

• Current Location

  INTENT TO USE SECTION

  Employee Name

  STEEL, ALYSSA PALADINO

• Attorney Docket Number

  R08782000300

  Attorney Name

  Douglas R. Wolf

  Law Office Assigned Location Code

  N60

• Owners

  • ReNAgade Therapeutics Management Inc.

Case File Statements

• GS0051: Pharmaceutical and/or biological preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy containing polypeptide encoding nucleic acids for the prevention and/or treatment of rare diseases, cancers, diabetes, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders and reproductive disorders; Pharmaceutical and/or biological preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for in vitro, in vivo, or ex vivo delivery to a cell, organ, tissue, or body; Pharmaceutical and/or biological preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for the treatment of infectious diseases, blood disorders, diabetes, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy, for the prevention of osteoporosis; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for the treatment of immune system related diseases and disorders; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics for the treatment of infectious diseases; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for the treatment of viral infections; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for treating diabetes; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for use in chemotherapy; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy, namely, antivirals; Vaccine preparations; Vaccines; Anti-epileptic pharmaceutical preparations; veterinarian vaccine preparations; Medical preparations for the treatment of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; Mixed biological preparations for the prevention and treatment of infectious diseases; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics, namely, linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy for the treatment of viral and joint diseases
• GS0011: Biochemicals, namely, protein-encoding nucleic acids in the nature of double-stranded and single-stranded DNA, RNA, and chimeric DNA and RNA molecules in linear and/or circular form and polypeptide-encoding nucleic acids in the nature of double-stranded and single-stranded DNA, RNA, or chimeric DNA and RNA molecules in linear and/or circular form for in vivo, ex vivo, on vivo or in vitro scientific research and medical research, and for use in the manufacture of RNA therapeutics and DNA therapeutics which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy; Biochemicals, namely, protein-encoding nucleic acids in the nature of double-stranded and single-stranded DNA, RNA, or chimeric DNA and RNA molecules in linear and/or circular form and polypeptide-encoding nucleic acids in the nature of double-stranded and single-stranded DNA, RNA, or chimeric DNA and RNA molecules in linear and/or circular form for use in the manufacture of pharmaceuticals for treating cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; Reagents for testing sterility of pharmaceuticals; Diagnostic reagents for scientific or research use; chemicals for use in biotherapeutics, biosimilars and therapeutics product development and manufacturing processes; polypeptide encoding nucleic acids for laboratory use; Biochemical catalysts; Biochemical preparations for scientific purposes; Biochemical reagents commonly known as probes, for detecting and analyzing molecules in protein or nucleotide arrays; Diagnostic preparations for clinical or medical laboratory use; Diagnostic preparations for scientific or research use; Diagnostic preparations used in science; Nucleic acid for laboratory use; Protein in raw material form for scientific and medical research; Reagents for research purposes; Reagents for scientific and research use; Active chemical ingredients for use in the manufacture of pharmaceuticals for treating rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders and reproductive disorders; Antioxidants for use in the manufacture of pharmaceuticals; Biochemicals for in vitro, in vivo, and ex vivo scientific use; Biochemicals, namely, polypeptides for in vitro research use; Biochemicals, namely, polynucleotides for in vitro and in vivo scientific and research purposes; Biomedical compounds, namely, peptide substrates used in analyzing and detecting certain toxins for laboratory or research use; Catalysts for chemical and biochemical processes; Cells for scientific, laboratory or medical research; Chemical additives for use in the manufacture of pharmaceuticals; Chemicals for use in the biochemical and chemical industry; Chemicals for use in the purification of proteins for in vitro use; Diagnostic reagents for clinical or medical laboratory use; Diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; Enzymes for use in protein hydrolysis; Immunohistochemistry detection kits consisting of mouse secondary reagents, DAB chromogens, DAB buffers, peroxidase blocking reagent, and hematoxylin, for anatomic pathology purposes in the medical diagnostics industry; Laboratory chemicals, namely, an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; Nucleic acid isolation and purification kit consisting primarily of reagents and magnetic beads for scientific research purposes; Plant extracts for use in the manufacture of pharmaceuticals; Protein arrays and nucleotide arrays for scientific and medical research; Reagents for scientific or medical research use
• DS0000: "THERAPEUTICS"
• GS0421: Scientific research in the fields of pharmaceuticals, vaccines, medicine, biologics, biotherapeutics, biosimilars and therapeutics; design, engineering, genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy and cell therapy, research, development and testing services in the field of pharmaceutical and/or biological preparations and substances, namely, nucleic acid therapeutics and delivery vehicles in the nature of RNA therapeutics and DNA therapeutics in the nature of linear and/or circular DNA or RNA molecules which may constitute and/or encode one or more components utilized in genome editing, gene editing, genome engineering, recombineering, gene modulation, transcriptional regulation, transcriptional modulation, gene therapy or cell therapy; Design, engineering, research, development and testing services in the field of polymeric materials, polymer synthesis, and materials customization for medical, scientific, and technological applications; Medical and scientific research in the field of cancer treatment and diagnosis; Research and development in the pharmaceutical and biotechnology fields; Research and development of vaccines and medicines; Research and development services in the field of antibodies; Scientific research for medical purposes in the area of cancerous diseases; Scientific research for medical purposes in the field of nucleic acids, inhibitory nucleic acids, protein-encoding nucleic acids and polypeptide-encoding nucleic acids; Pharmaceutical research and development; Product research and development; Scientific research and development; Vaccine research and development

Case File Event Statements

• 10/8/2022 - 2 years ago

  1 - NEW APPLICATION ENTERED Type: NWAP

• 10/22/2022 - 2 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 7/19/2023 - a year ago

  3 - ASSIGNED TO EXAMINER Type: DOCK

• 8/7/2023 - a year ago

  4 - NON-FINAL ACTION WRITTEN Type: CNRT

• 8/7/2023 - a year ago

  5 - NON-FINAL ACTION E-MAILED Type: GNRT

• 8/7/2023 - a year ago

  6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 10/4/2023 - a year ago

  7 - ASSIGNED TO EXAMINER Type: DOCK

• 11/6/2023 - a year ago

  8 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 11/6/2023 - a year ago

  9 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 11/7/2023 - a year ago

  10 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 11/14/2023 - a year ago

  11 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 11/29/2023 - a year ago

  12 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 12/19/2023 - a year ago

  13 - PUBLISHED FOR OPPOSITION Type: PUBO

• 12/19/2023 - a year ago

  14 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 2/13/2024 - 12 months ago

  15 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM

• 2/20/2024 - 11 months ago

  16 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP

• 2/20/2024 - 11 months ago

  19 - TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS Type: EWAF

• 2/20/2024 - 11 months ago

  18 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA

• 7/31/2024 - 6 months ago

  20 - SOU TEAS EXTENSION RECEIVED Type: EEXT

• 7/31/2024 - 6 months ago

  23 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA

• 7/31/2024 - 6 months ago

  21 - SOU EXTENSION 1 FILED Type: EXT1

• 7/31/2024 - 6 months ago

  22 - SOU EXTENSION 1 GRANTED Type: EX1G

• 2/20/2024 - 11 months ago

  17 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA